Giving Tamiflu too late in critical flu doubles the risk of death
Critically ill flu patients who start Tamiflu only about five days into symptoms face roughly double the 90-day risk of death compared with no antiviral; an mRNA flu vaccine is approved, but only 50-64-year-olds got traditional approval.
The video won't play here. Listen to the audio instead:
The argument · tap a timestamp to hear it
The money is still appropriated; the people who could spend it are gone
Daniel points to an Alzheimer's program Congress still funded with $41 million this year and a tobacco-control office funded with $246 million: the appropriations went through, but the experts who were supposed to execute them have been laid off by the Trump administration or placed on leave and barred from working. On the ledger the programs are alive; in function they are dead. The conclusion is not a vague complaint about budget cuts but a precise distinction: "the money exists" and "the capacity to do the work exists" are two different things, and money approved by the legislature cannot buy back the positions that were cut.
— Daniel GriffinThis DRC Ebola outbreak is the deadliest one ever recorded
Africa CDC's language is heavier than the usual news coverage: the current DRC Ebola outbreak is already the deadliest in the country's history and the fastest-growing on record, with a case fatality rate approaching 50% and roughly one life taken every 30 minutes; there are 5105 confirmed cases and 2420 deaths. They do not treat the figures as a death tally but call for a humanitarian ceasefire, guaranteed access for health workers, and the lifting of unscientific travel bans, while urging African local production of diagnostics, treatments and vaccines.
— Daniel GriffinVaccines don't block infection, but they cut transmission about 400-fold
A systematic review found 70 people who had been vaccinated against measles and still transmitted the virus, producing 237 second-generation cases, with 812 cases traced in the end; so "the vaccine prevents infection" does not hold absolutely. Daniel's conversion matters more: one unvaccinated person infects 20 others on average, while among vaccinated people it takes roughly 20 of them to produce a single secondary case, a difference in transmission risk of about 400-fold. He stresses again and again that vaccines prevent severe disease and do not prevent all infection and transmission, and that what deserves attention is immunity gaps at the school and school-district level, not the average coverage rate.
— Daniel GriffinThe mRNA flu vaccine is proven superior only in 50-64-year-olds
FDA approved Moderna's mRNA-1010 flu vaccine: traditional approval for ages 50-64, accelerated approval for 65 and over. The key evidence is in the 50-64 group, where the vaccine reduced disease by 27% relative to a standard dose; for 65 and over it only demonstrated "no worse than the high-dose vaccine" and has not yet shown superiority, hence the conservative approval. Vincent says plainly that he falls in the 50-64 band and would choose the mRNA version; Daniel expects it to be available for shots in late September or early October.
— Daniel GriffinTamiflu's problem is not that it fails, but that it arrives too late
A randomized controlled trial in 442 critically ill flu patients found 90-day mortality of 13.7% with no antiviral, versus 19.8% and 19.4% in the 5-day and 10-day Tamiflu arms, an adjusted OR of about 2.1 and a 98% posterior probability of harm. Daniel points to the reasons: enrollees had been symptomatic for about 5 days on average and most were already on high-flow oxygen or intubated, and the evidence for early antiviral use within 48 hours has not been overturned; the real signal may be that giving the drug too late is useless or even harmful, and that the observation endpoint should be extended to 90 days.
— Daniel GriffinWinters when RSV overwhelms children's hospitals may not return
A French nationwide matched cohort enrolled 74672 infants in 2023 and 175526 in 2024; among nirsevimab recipients, the first-year rate of RSV lower-respiratory-tract hospitalization was 0.8% versus 2.4% in the unimmunized group (in 2024, 0.5% vs 1.9%), for effectiveness of 66% and 72% respectively; there was no protection in the second year. A separate UK study of maternal RSV vaccination during pregnancy put adjusted effectiveness against hospitalization in infants under 6 months at about 61%. Daniel's hope is a concrete one: the scene of children's hospitals swamped by RSV each winter may be rewritten.
— Daniel GriffinData on 150,000 pregnant women shows no link to miscarriage
This item responds to a Republican official treating Fauci's old text messages as evidence that vaccines cause miscarriage. Daniel starts with the background: whether or not a woman is vaccinated, 10%-20% of known pregnancies end in miscarriage. A 2022 pooled analysis of 23 studies covering roughly 118,000 women vaccinated during pregnancy, and a 2023 set of 21 studies covering 150,000 people, both found no association with miscarriage, and the 2022 analysis in fact found a reduced risk of stillbirth. The comparison figures are starker: in the first half of 2020, nearly one third of pregnant women infected with COVID required hospitalization, against only 6% of non-pregnant women the same age, with a 70% higher risk of death.
— Daniel GriffinViral infection outlasts the acute phase; discharge is not a cure
A JID commentary takes apart three myths: viral infection is not merely an acute respiratory problem, and brings fatigue, brain fog and declining physical function; long-term damage is not confined to the very young, the very old and the immunocompromised, as a marathon runner infected with SARS-CoV-2 could not run three miles three weeks later; and third, "after the acute phase we provided the care that was needed" does not hold, since many specialty long COVID clinics in the United States have closed because they do not make money. Daniel uses this to argue repeatedly for pushing the endpoint of interventions out to 90 days and beyond, rather than counting a patient's discharge as success.
— Daniel GriffinIn their own words · checked verbatim
They appear to be alive, at least according to legislation and congressional appropriations. But functionally, they are dead or nearly dead because the CDC experts who did the work were laid off by President Donald Trump's administration or remain on leave.
Daniel Griffin3:07
Behind every number is a person, a family, a community living with fear and loss. These deaths are not inevitable.
Africa CDC10:18
measles transmission from vaccinated cases, although relatively uncommon, must be considered because these can contribute.
Daniel Griffin13:28
vaccines prevent severe disease, but they don't prevent infection, and they do not prevent all transmission.
Daniel Griffin14:28
treatment with tamiflu in critical patients is not effective. And it's actually highly likely that it increases the 90 day mortality.
Daniel Griffin26:44
Perfect communication skills won't allay the fears of a patient who refuses Tylenol because a politician said it causes autism.
Maria (listener mail)53:46
there is a widespread, pervasive propaganda campaign that is anti-science. It's anti-medicine. And it's aimed to undermine so much of what we've built over time.
Daniel Griffin54:46
Figures
| CDC Alzheimer's program funded this year but left with no staff | $41 million | 3:07 |
| CDC tobacco-control office funding this year | $246 million | 3:07 |
| Cumulative cyclosporiasis cases in this outbreak | 15716 confirmed + 11841 pending review, about 27000 (about 1180 last year) | 5:10 |
| DRC Ebola confirmed cases and deaths | 5105 confirmed, 2420 deaths | 10:18 |
| Total across cohort studies of vaccinated measles transmitters | 70 vaccinated people caused 237 second-generation cases, with 812 cases traced in all | 13:28 |
| US kindergarten non-medical vaccine exemption rate, 2025-26 school year | about 4%, up 18% from the previous school year | 17:31 |
| mRNA flu vaccine effectiveness relative to standard dose | 27% | 22:41 |
| 90-day mortality in the critical-flu Tamiflu trial (none / 5 days / 10 days) | 13.7% / 19.8% / 19.4% | 25:41 |
| nirsevimab effectiveness against RSV hospitalization | 66% in 2023, 72% in 2024 | 35:17 |
| UK maternal RSV vaccine effectiveness against hospitalization in infants under 6 months | 61%; about 76% under 3 months | 37:21 |
| Hospitalization among pregnant women infected with COVID vs non-pregnant women the same age | nearly 1/3 vs 6% | 40:21 |
Glossary
- cyclosporiasis
- A foodborne parasitic disease acquired from contaminated produce; the oocysts are extremely hard to wash off, and the typical presentation is persistent watery diarrhea.
- New World screwworm
- Fly larvae that infest open wounds in warm-blooded animals and eat flesh; in recent years it has spread from South America toward North America and also infects pets.
- nirsevimab
- A long-acting RSV monoclonal antibody injected into infants; one shot covers an entire season, with no waiting for active immunity to mature.
- test-negative case-control
- Compares the vaccination histories of test-positive and test-negative patients within the same hospitalized population to estimate real-world vaccine effectiveness.
- adaptive analysis
- A trial sets rules in advance to pause and look at results midstream, in order to decide whether to stop enrollment or change the later arms.
- non-medical exemption
- Lets parents keep a child unvaccinated and still enrolled in school on religious or belief grounds, with no tie to any medical contraindication.
How to listen
For ICU and hospital clinicians who prescribe flu antivirals, for anyone over 50 choosing a flu vaccine, and for family members agonizing over RSV/COVID vaccination timing for pregnant women and infants.
The 7:15-9:16 breakdown of how the canine screwworm drug works has no bearing on human clinical practice; skip it.